

# BIO-FLARE: to improve understanding of why some people with rheumatoid arthritis experience flares, and what is happening to the joint when they occur

<b>Submission date</b> 08/04/2019	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 27/06/2019	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 23/04/2025	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Rheumatoid arthritis (RA) is a relapsing and remitting autoimmune disease. Whilst a considerable amount is understood about factors which may contribute to the development of RA and about disease mechanisms, nothing is known of the factors that trigger disease relapses (flares), converting the disease from an inactive to an active state. The underpinning mechanism (s) of flare has been difficult to study because they occur unpredictably. The researchers will study patients who flare to capture signals that may determine which patients are most likely to flare, as well as understand the biology behind the phenomenon of flare itself. This may eventually lead to future work on treatable targets in disease management.

### Who can participate?

Patients in remission from RA on traditional disease-modifying therapies (DMARDs), namely methotrexate, sulfasalazine, and/or hydroxychloroquine

### What does the study involve?

The patients stop taking their DMARDs and are closely followed-up by the research team. Previous research suggests 50% will experience flare, while the remainder will remain in remission. They have regular assessment of their disease activity (physical examination and questionnaires), along with clinical and research blood samples taken. Urine samples are taken at each visit. If a patient in the study experiences a flare, they have an ultrasound-guided synovial biopsy taken under local anaesthetic. Samples of blood, urine and synovium (joint lining) are analysed for gene expression, synovial cell subtypes, molecular pathways, immune cell profiles, and antibody status. After 6 months, if a patient does not experience a flare, they are referred back to their usual rheumatologist and may be able to remain off of DMARDs. If a patient experiences flare at any time, they receive steroid treatment and be referred back to their usual rheumatologist to restart their DMARDs.

What are the possible benefits and risks of participating?

Based on previous research performed at other centres and our own, it is expected that up to half of the patients with RA in remission may be able to stop their DMARD medication without an increase in their arthritis activity. DMARD medications have an associated small risk of serious side effects. By participating in this study patients will be helping to provide important data that may help to identify markers that can predict when, how and which people with RA will flare. While it may not necessarily be of direct benefit to the participant, it is hoped that this study will help us to understand more about rheumatoid arthritis, how it develops and what treatments will be effective. There is a risk that when patients stop taking their DMARD medication their arthritis may become more active, causing joint pain and swelling. It is difficult to predict the exact chance of this happening, but previous studies suggest that this may occur in around half of the patients. Patients who experience disease activity will be seen at short notice to confirm, before being referred rapidly back to their rheumatology team who would be able to restart DMARD medications. A steroid injection/course of steroid tablets may also be offered to help settle the arthritis

Where is the study run from?

University of Newcastle (UK)

When is the study starting and how long is it expected to run for?

July 2018 to June 2021

Who is funding the study?

Medical Research Council (UK)

Who is the main contact?

Katie Gray, [Katie.Gray@newcastle.ac.uk](mailto:Katie.Gray@newcastle.ac.uk)

## Contact information

### Type(s)

Public

### Contact name

Ms Katie Gray

### Contact details

Faculty of Medical Sciences, Newcastle University  
G22 Ground Floor Wolfson Building  
Framlington Place  
Newcastle upon Tyne  
United Kingdom  
NE2 4HH

-

[Katie.Gray@newcastle.ac.uk](mailto:Katie.Gray@newcastle.ac.uk)

### Type(s)

Scientific

### Contact name

Prof John Isaacs

**ORCID ID**

<http://orcid.org/0000-0002-6103-7056>

**Contact details**

Newcastle upon Tyne Hospitals NHS Foundation Trust  
Work Address Institute of Cellular Medicine  
4th Floor, Leech Building, Medical School  
Framlington Place  
Newcastle University  
Newcastle upon Tyne  
United Kingdom  
NE2 4HH  
+44 (0)1912085337  
[John.Isaacs@newcastle.ac.uk](mailto:John.Isaacs@newcastle.ac.uk)

**Additional identifiers****EudraCT/CTIS number**

Nil known

**IRAS number****ClinicalTrials.gov number**

Nil known

**Secondary identifying numbers**

CPMS 36953, MR/N026977/1

**Study information****Scientific Title**

BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study)

**Acronym**

BIO-FLARE

**Study objectives**

The aim of this study is to measure the immune dysfunction that patients with RA undergo immediately prior to experiencing a flare. The researchers will do this by analysing immune cell expression, autoantibody levels and subtypes, synovial (joint lining) tissue composition, metabolic and genetic factors.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 06/02/2018, North East - Newcastle & North Tyneside 1 Research Ethics Committee (HRA Jarrow, Jarrow Business Centre, Room 001, Rolling Mill Road, Jarrow, NE32 3DT; Tel: +44 (0)207 1048 084; Email: nrescommittee.northeast-newcastleandnorthtyneside1@nhs.net), ref: 17/NE/0386

## **Study design**

Non-randomised; Both; Design type: Treatment, Drug, Management of Care, Cohort study

## **Primary study design**

Interventional

## **Secondary study design**

Non randomised study

## **Study setting(s)**

Hospital

## **Study type(s)**

Treatment

## **Participant information sheet**

Not available in web format, please use the contact details to request a patient information sheet

## **Health condition(s) or problem(s) studied**

Rheumatoid arthritis

## **Interventions**

In this study, the researchers will recruit patients in remission from RA on traditional disease-modifying therapies (DMARDs), namely methotrexate, sulfasalazine, and/or hydroxychloroquine. These patients will then discontinue their DMARDs and be closely followed-up by the research team. Previous research suggests 50% will experience flare, while the remainder will remain in remission. They will have regular assessment of their disease activity (physical examination and questionnaires), along with clinical and research blood samples taken. Urine samples will be taken at each visit. If a patient in the study experiences a flare, they will have an ultrasound-guided synovial biopsy taken under local anaesthetic. Samples of blood, urine and synovium (joint lining) will be analysed for gene expression, synovial cell subtypes, molecular pathways, immune cell profiles, and antibody status.

After 6 months, if a patient does not experience a flare, they will be referred back to their usual rheumatologist and may be able to remain off of DMARDs. If a patient experiences flare at any time, they will receive steroid treatment and be referred back to their usual rheumatologist to restart their DMARDs.

## **Intervention Type**

Other

## **Primary outcome measure**

The proportion of patients who experience a confirmed flare as described in Section 5.9 of the Protocol (DAS28-CRP  $\geq$  3.2 or DAS28-CRP  $\geq$  2.4 on two occasions 7-14 days apart) at any time up

to/including 24 weeks after cessation of treatment:

1. Disease flare occurrence (proportion at 24 weeks)
2. Time to disease flare (also used to estimate proportion at 24 weeks)

### **Secondary outcome measures**

1. Individual components of the primary outcome of 'flare' (DAS28-CRP  $\geq 3.2$  or DAS28-CRP  $\geq 2.4$  on two occasions 7-14 days apart) at any time up to/including 24 weeks after cessation of treatment. The individual components are:
    - 1.1. Tender joint count
    - 1.2. Swollen joint count
    - 1.3. Visual analogue scale (patient)
    - 1.4. CRP
  2. Immune cell subsets and their activation status. The researchers will be using conventional fluorescence-based flow cytometry and also mass cytometry (CyTOF) to measure the immune cell subsets, specifically the T cells, B cells, dendritic cells and monocytes. This will be done in batches to reduce batch effect and cytometer drift. All of the samples from one patient will be analysed at a single timepoint (following stabilisation and freezing of the samples)
  3. Autoantibody profiles. The researchers will transfer serum samples to their industrial partner Orgentec for assessment of antibody specificity. Antigen affinity of key autoantibodies will be measured using BIAcore surface plasmon resonance or similar techniques. Circulating cytokines will be measured in serum and/or plasma using immunoassays or ELISAs
  4. Epigenetic profiles: high-order chromatin structures in immune cells, such as PBMC, CD4+ T cells and CD14+ monocytes, will be evaluated on the EpiSwitch<sup>TM</sup> PCR platform (in partnership with Oxford Biodynamics). Differentiating signatures will be refined using binary EpiSwitch<sup>TM</sup> scores and logistical regression modelling, and the accuracy and robustness of the predictive model determined by ROC analysis.
  5. T-cell receptor excision circles as a marker of thymic activity
  6. Synovial cell lineages present, including stromal cell subtypes, as well as their associated cytokines and chemokines. Stromal and leukocyte subpopulations will be sorted from synovial biopsy samples by flow cytometry and DNA/RNA/miRNA will be extracted for further downstream transcriptomic analysis. Where possible, key findings will be validated by histology in matched tissue sections, alongside appropriate in vitro functional assays
- Samples are collected September 2018 – October 2020

### **Overall study start date**

01/04/2017

### **Completion date**

30/06/2021

## **Eligibility**

### **Key inclusion criteria**

1. Diagnosis of rheumatoid arthritis according to the 1987 ACR or 2010 ACR/EULAR classification criteria (applied at any time since diagnosis)
2. Current single or combination use of methotrexate, sulfasalazine and/or hydroxychloroquine. No escalations in dose are permitted in the six months prior to enrolment, although dose reductions in this time are permitted
3. Arthritis currently in remission, as judged clinically by referring healthcare professional
4. Patient and referring clinician willing to consider DMARD withdrawal
5. Age > 16 at time of first diagnosis with RA, and > 18 at time of recruitment

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

Planned Sample Size: 181; UK Sample Size: 181

**Total final enrolment**

137

**Key exclusion criteria**

1. Inability to provide informed consent
2. Current participation or follow-up within another ongoing clinical interventional trial
3. Current pregnancy, or pregnancy planned within next 6 months
4. Major surgery planned within next 6 months (definition of major surgery at discretion of screening clinician)
5. Immunisation within the past 4 weeks
6. Received steroids within past 3 months (oral, parenteral or intra-articular)
7. Use of any DMARD other than methotrexate, sulfasalazine or hydroxychloroquine within the past 6 months (or past 12 months for leflunomide)
8. Increase in the dose of any DMARD in the 6 months prior to screening.
9. Use of biologic therapy within the past 6 months
10. Prior use of cell-depleting biologic therapies
11. Haemoglobin < 9g/L at baseline
12. Contraindication to synovial biopsy – e.g. bleeding diathesis or prolonged use of anticoagulant therapy (warfarin or other direct oral anticoagulants e.g. rivaroxaban)
13. Active crystal arthropathy

\*Topical, inhaled and intra-nasal steroids are permitted

**Date of first enrolment**

02/07/2018

**Date of final enrolment**

14/12/2020

**Locations****Countries of recruitment**

England

Scotland

United Kingdom

**Study participating centre**

**NHS Greater Glasgow and Clyde Health Board**

NHS Greater Glasgow and Clyde  
Clinical Research Facility, Glasgow Royal Infirmary  
New Lister Building, 10 Alexandra Parade  
Glasgow  
United Kingdom  
G31 2ER

**Study participating centre**

**University Hospitals Birmingham NHS Foundation Trust**

Trust HQ, PO Box 9551  
Queen Elizabeth Medical Centre  
Edgbaston  
Birmingham  
United Kingdom  
B15 2TH

**Study participating centre**

**Sandwell and West Birmingham Hospitals NHS Trust**

City Hospital  
Dudley Road  
Birmingham  
United Kingdom  
B18 7QH

**Study participating centre**

**The Newcastle Upon Tyne Hospitals NHS Foundation Trust**

Freeman Hospital  
Freeman Road  
High Heaton  
Newcastle-upon-Tyne  
United Kingdom  
NE7 7DN

**Study participating centre**

**Northumbria Healthcare NHS Foundation Trust**

Rake Lane  
North Shields

United Kingdom  
NE29 8NH

**Study participating centre**

**Gateshead Health NHS Foundation Trust**  
Queen Elizabeth Hospital  
Gateshead  
United Kingdom  
NE9 6SX

**Study participating centre**

**City Hospitals Sunderland NHS Foundation Trust**  
Sunderland Royal Hospital  
Kayll Road  
Sunderland  
United Kingdom  
SR4 7TP

## **Sponsor information**

**Organisation**

The Newcastle Upon Tyne Hospitals NHS Foundation Trust

**Sponsor details**

Freeman Hospital  
Freeman Road  
High Heaton  
Newcastle-Upon-Tyne  
England  
United Kingdom  
NE7 7DN

**Sponsor type**

Hospital/treatment centre

**ROR**

<https://ror.org/05p40t847>

## **Funder(s)**

**Funder type**



Research council

**Funder Name**

Medical Research Council

**Alternative Name(s)**

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

**Results and Publications**

**Publication and dissemination plan**

- 1. Peer-reviewed scientific journals
- 2. Internal report
- 3. Conference presentation
- 4. Anonymous RNA sequence data will be made freely available online via the publicly-accessible National Institutes of Health (NIH) Gene Expression Omnibus (GEO)

**Intention to publish date**

30/06/2025

**Individual participant data (IPD) sharing plan**

The data sharing plans for the current study are unknown and will be made available at a later date

**IPD sharing plan summary**

Data sharing statement to be made available at a later date

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Interim results article</a>		09/04/2025	23/04/2025	Yes	No